Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04911127 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT04911127 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 67 participants.
The verdict
NCT04911127, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.
Interventions
- DRUG Placebo capsules
- DRUG 200mg Cannabidiol by capsules twice daily
- DRUG 400mg Cannabidiol by capsules twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-10-05 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04911127
The ClinicalTrials.gov registry entry for NCT04911127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo capsules is the first listed.
NCT04911127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04911127 about?
NCT04911127 is a clinical study titled "Therapeutic Response of Cannabidiol in Rheumatoid Arthritis". The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.
What is the current status of trial NCT04911127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2021-10-05. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04911127?
The interventions under investigation include: Placebo capsules (DRUG), 200mg Cannabidiol by capsules twice daily (DRUG), 400mg Cannabidiol by capsules twice daily (DRUG).
Who is sponsoring clinical trial NCT04911127?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.